Therapeutic plasma exchange in neurology: 2012

Journal of Clinical Apheresis

Volumn 28, Issue 1, 2013, Pages 16-19

  Cortese, Irene ^a   Cornblath, David R ^b  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

apheresis; CIDP; Guillain Barr syndrome; myasthenia gravis; neurologic indications; plasmapheresis; therapeutic plasma exchange

Indexed keywords

ACUTE DISSEMINATED ENCEPHALOMYELITIS; AMYOTROPHIC LATERAL SCLEROSIS; CHOREA MINOR; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; CONFERENCE PAPER; DERMATOMYOSITIS; EATON LAMBERT SYNDROME; GUILLAIN BARRE SYNDROME; HUMAN; INCLUSION BODY MYOSITIS; MEDICAL SOCIETY; MULTIPLE SCLEROSIS; MYASTHENIA GRAVIS; MYELOOPTIC NEUROPATHY; NEUROLOGIC DISEASE; PARANEOPLASTIC NEUROPATHY; PLASMAPHERESIS; POEMS SYNDROME; POLYMYOSITIS; POLYNEUROPATHY; REFSUM DISEASE; STIFF MAN SYNDROME;

AUTOANTIBODIES; AUTOIMMUNE DISEASES OF THE NERVOUS SYSTEM; EVIDENCE-BASED MEDICINE; HUMANS; NERVOUS SYSTEM DISEASES; NEUROLOGY; PARANEOPLASTIC POLYNEUROPATHY; PLASMA EXCHANGE; PLASMAPHERESIS; PRACTICE GUIDELINES AS TOPIC; TREATMENT OUTCOME;

EID: 84874023756     PISSN: 07332459     EISSN: 10981101     Source Type: Journal    
DOI: 10.1002/jca.21266     Document Type: Conference Paper

References (24)

1. Lehmann HC, Hartung HP,. Plasma exchange and intravenous immunoglobulins: mechanism of action in immune-mediated neuropathies. J Neuroimmunol 2011; 231: 61-69.
2. Szczepiorkowski ZM, Winters JL, Bandarenko N, Kim HC, Linenberger ML, Marques MB, Sarode, R, Schwartz J, Weinstein R, Shaz BH,. Apheresis Applications Committee of the American Society for Apheresis. Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the apheresis applications committee of the american society for apheresis. J Clin Apher 2010; 25: 83-177.
3. Cortese I, Chaudhry V, So YT, Cantor F, Cornblath DR, Rae-Grant A,. Assessment subcommittee of the American academy of neurology: Report of the therapeutics and technology evidence-based guideline update: plasmapheresis in neurologic disorders. Neurology 2011; 76; 294-300.
4. Mehndiratta MM, Hughes RAC, Agarwal P,. Plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev 2004;3:CD003280.
5. Raphaël JC, Chevret S, Hughes RAC, Annane D,. Plasma exchange for Guillain-Barré syndrome. Cochrane Database Syst Rev 2012;7:CD001798.
6. Gajdos P, Chevret S, Toyka KV,. Plasma exchange for generalized myasthenia gravis. Cochrane Database Syst Rev 2002;4:CD002275.
7. Keogh M, Sedehizadeh S, Maddison P,. Treatment for Lambert-Eaton myasthenic syndrome. Cochrane Database Syst Rev 2011;2:CD003279.
8. Allen D, Lunn MPT, Niermeijer J, Nobile-Orazio E,. Treatment for IgG and IgA paraproteinaemic neuropathy. Cochrane Database Syst Rev 2007;1:CD005376.
9. Lunn MPT, Nobile-Orazio E,. Immunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies. Cochrane Database Syst Rev 2012;5:CD002827.
10. Cornblath DR, Braine HG, Dyck PJ, Mendell JR, Rodriguez M, Ropper AH, Wolinsky JS,. Assessment of plasmapheresis: report of the therapeutics and technology assessment subcommittee of the American academy of neurology. Neurology 1996; 47: 840-843.
11. Köller H, Kieseier BC, Jander S, Hartung HP,. Chronic inflammatory demyelinating polyneuropathy. N Engl J Med 2005; 352: 1343-1356.
12. Joint Task Force of the EFNS and the PNS. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society-first revision. J Peripher Nerv Syst 2010; 15: 1-9. Erratum in: J Peripher Nerv Syst 2010;15:373.
13. Mehndiratta MM, Hughes RAC,. Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev 2002;1:CD002062.
14. Eftimov F, Winer JB, Vermeulen M, de Haan R, van Schaik IN,. Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev 2009;1:CD001797.
15. Yuki N,. Guillain-Barré syndrome and anti-ganglioside antibodies: a clinician-scientist's journey. Proc Jpn Acad Ser B Phys Biol Sci 2012; 88: 299-326.
16. Yuki N, Hartung HP,. Guillain-Barré syndrome. N Engl J Med 2012; 366: 2294-2304.
17. Khan F, Ng L, Amatya B, Brand C, Turner-Stokes L,. Multidisciplinary care for Guillain-Barré syndrome. Cochrane Database Syst Rev 2010;10:CD008505.
18. Hughes RAC, Swan AV, van Doorn PA,. Intravenous immunoglobulin for Guillain-Barré syndrome. Cochrane Database Syst Rev 2012 7:CD002063.
19. Dau PC, Lindstrom JM, Cassel CK, Denys EH, Shev EE, Spitler LE,. Plasmapheresis and immunosuppressive drug therapy in myasthenia gravis. N Engl J Med 1977; 297: 1134-1140.
20. Hoch W, McConville J, Helms S, Newsom-Davis J, Melms A, Vincent A,. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med 2001; 7: 365-368.
21. Guptill JT, Sanders DB, Evoli A,. Anti-MuSK antibody myasthenia gravis: clinical findings and response to treatment in two large cohorts. Muscle Nerve 2011; 44: 36-40.
22. Joint Task Force of the EFNS and the PNS. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of paraproteinemic demyelinating neuropathies. Report of a Joint Task Force of the European Federation of Neurological Societies and the Peripheral Nerve Society-first revision. J Peripher Nerv Syst 2010; 15: 185-195.
23. Meggeneder J, Huff CA, Cornblath DR,. Lymphoplasmacytic lymphoma and neuropathy: long-term follow-up. J Peripher Nerv Syst 2012; 17: 260.
24. Titulaer MJ, Lang B, Verschuuren JJ,. Lambert-Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies. Lancet Neurol 2011; 10: 1098-1107.